Pleural effusion drug market to reach $5.31 billion by 2030

The global pleural effusion drug market is projected to grow from $3.32 billion in 2025 to $5.31 billion by 2030, driven by rising cardiovascular disease, respiratory illness, and healthcare spending. North America is expected to remain the largest market in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - The pleural effusion drug market is expanding as more patients need treatment for fluid buildup linked to heart failure, infections, inflammation and cancer. - Faster market growth signals higher demand for hospital therapies, targeted oncology drugs and easier-to-use respiratory treatments. - The market’s growth is tied to broader pressure on health systems from aging populations and rising chronic disease.

What happened: - The Business Research Company released its Pleural Effusion Drug Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on July 6, 2026. - The report estimates the market will rise from $3.32 billion in 2025 to $3.64 billion in 2026. - The report forecasts the market will reach $5.31 billion by 2030. - The report places the market at a 9.6% CAGR over the historical period and a 9.9% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Pleural effusion drugs are used to manage excess fluid in the pleural cavity around the lungs. - These drugs target causes such as infection, inflammation, heart failure and cancer. - The medications also aim to relieve shortness of breath and chest pain. - Historical growth has been driven by rising respiratory illness and lung infections. - More pleural effusion cases related to heart failure have also supported demand. - Expanded use of diuretics and antibiotics in hospitals has contributed to market growth. - Better critical and emergency care infrastructure has supported treatment access. - Greater awareness of early respiratory disease management has helped lift demand. - Future growth is expected to come from wider use of targeted oncology therapies for malignant pleural effusion. - Precision medicine advances for respiratory conditions are also expected to support demand. - Demand is rising for minimally invasive drug delivery systems and home-based respiratory treatment options. - Increased investment in biologics and advanced anti-inflammatory drugs is expected to shape the market. - Anticipated product trends include biomarker-driven drug development, biologic therapies to reduce pleural fluid, combination regimens and long-acting injectable formulations. - North America is expected to remain the largest regional market in 2025. - Asia-Pacific is forecast to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, and the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The market outlook suggests pleural effusion treatment is shifting from broadly used supportive drugs toward more personalized and technologically advanced therapies. - The regional split points to mature demand in North America and faster expansion in markets where healthcare access and treatment adoption are still increasing. - Rising healthcare spending likely supports both diagnosis rates and access to specialty medicines, which can widen the addressable market. - The cited cardiovascular mortality figures underline why pleural effusion remains a downstream treatment need, not a standalone disease category.

What's next: - The market is expected to keep advancing as oncology, biologics and precision-medicine pipelines mature. - Drug makers are likely to focus on delivery methods that improve symptom control and reduce treatment burden. - Healthcare systems may see more use of home-based and minimally invasive care models for respiratory conditions.

The bottom line: - Pleural effusion drugs are moving into a stronger growth phase, powered by chronic disease burden, higher healthcare spending and a shift toward more targeted treatments.